{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-211645","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.725446+00:00","generated_at":"2026-05-31T06:35:21.429904+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aldeyra appoints Michael Alfieri as principal financial officer, Bruce Greenberg steps down","bullets":["Michael Alfieri appointed as principal financial officer and principal accounting officer, effective Aug 31, 2024, via consulting agreement with Danforth Global, Inc.","Bruce Greenberg stepped down from positions including SVP Finance, Interim CFO, and principal accounting officer as of Aug 31, 2024.","Greenberg receives separation: six months base salary, lump-sum $125,895, and COBRA premium payments for up to six months.","Greenberg will provide consulting services through Nov 30, 2024, with continued vesting of outstanding stock options."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-211645","json":"https://secwatch.observer/filing/0001193125-24-211645.json","markdown":"https://secwatch.observer/filing/0001193125-24-211645.md","text":"https://secwatch.observer/filing/0001193125-24-211645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/d862679d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:35:21.429904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27b4b2518c","claim":"Michael Alfieri was appointed as principal financial officer and principal accounting officer at Aldeyra Therapeutics, Inc..","evidence_excerpt":"On August 29, 2024, the board of directors of Aldeyra Therapeutics, Inc. (the “Company”) approved the appointment of Michael Alfieri as the Company’s principal financial officer and principal accounting officer effective as of August 31, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"72825c376b","claim":"Bruce Greenberg departed as Senior Vice President of Finance, Interim Chief Financial Officer at Aldeyra Therapeutics, Inc..","evidence_excerpt":"As previously disclosed by the Company, Bruce Greenberg stepped down from his positions with the Company, including as the Company’s Senior Vice President of Finance, Interim Chief Financial Officer and principal financial officer and principal accounting officer as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Senior Vice President of Finance, Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}